BioVie completes Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson’s disease

BioVie Inc. Class A

BioVie Inc. Class A

BIVI

0.00
  • BioVie completed the last patient evaluation visit in its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson’s disease.
  • Topline results have not been presented yet; they are scheduled for release in Q3 2026.
  • The trial was set up to gauge whether bezisterim can deliver clinically meaningful improvements across motor and non-motor symptoms to support the design of Phase 3 registrational studies.
  • The 20-week study randomized 57 patients 1:1 to bezisterim or placebo, targeting patients not treated with carbidopa/levodopa.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9721528) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.